Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X8TS
|
|||
| Former ID |
DNCL002178
|
|||
| Drug Name |
RRx-001
|
|||
| Synonyms |
RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1] | |
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [2] | ||
| Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 2 | [3] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [3] | ||
| Ovarian epithelial cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [3] | ||
| Anaplastic glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [3], [4] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [3] | ||
| Company |
RadioRx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H6BrN3O5
|
|||
| Canonical SMILES |
C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-]
|
|||
| InChI |
1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2
|
|||
| InChIKey |
JODKFOVZURLVTG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 925206-65-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free radical (FRD) | Target Info | Modulator | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03699956) RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02452970) RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.